Despite the remarkable responses check details of most patients, a small but significant fraction of

patients develops clinical resistance to the TKIs, some of which is attributed to the BCR-ABL kinase domain mutations affecting TKI binding and activity. The recently approved third-generation TKI ponatinib showed remarkable activity in the patients with multi-TKI-resistant disease. Particularly impressive was its efficacy in patients with T315I mutation that is resistant to all other TKIs. In lieu of the current emphasis on achieving earlier and more profound responses and excellent activity of ponatinib in the refractory setting, its optimal position among the available armamentarium of agents is being established. (C) 2013 AACR.”
“Aims and purpose To identify selleck kinase inhibitor patterns and rates of adherence with travoprost eye drops using the Travatan dosing aid (TDA) and to present a method for graphically presenting adherence data.\n\nMethods A prospective observational cohort study of patients on travoprost (prostaglandin) monotherapy. Patients were dispensed a TDA and followed up after approximately 3 months of usage. Data were downloaded from the TDA into a computer for analysis. Analysis used inter-dose intervals (the time between each dosing) to look at adherence between days 4 and 75.\n\nResults In all,

100 patients were invited to participate, 53 agreed and complete TDA data sets were obtained from 37. In total 23 of the complete data sets showed good adherence (dosing within +/- 4 h of the agreed dosing time on 480% of occasions), 3 patients discontinued usage before 75 days, 4 showed frequent drug GDC-0973 molecular weight holidays (no dosing for >= 8 days) and 7 frequently missed doses with adherence rates of <60%. Of the 16 patients for whom no TDA data was obtained, 5 were lost to follow-up, 4 had faulty/damaged TDAs, 3 changed medication, 3 preferred not to use the TDA, and 1 was hospitalized.\n\nConclusions There were four easily defined patterns of adherence; (1) good adherence; (2) discontinued usage; (3) frequent drug holidays;

and (4) frequent missed doses with low adherence rates. A new method for graphically presenting adherence data helps clinicians identify the pattern of usage and is a valuable aid to the overall management of patients on travoprost therapy. Eye (2010) 24, 1338-1343; doi:10.1038/eye.2010.27; published online 26 March 2010″
“Titania and composite (Ag, Au, W) titania coatings were prepared on glass microscope slides via a sol-gel dip-coating method. The resulting coatings were characterised by X-ray diffraction, Raman, scanning electron microscopy (SEM), wavelength dispersive X-ray (WDX), Brunauer-Emmett-Teller (BET) surface area analysis, atomic force microscopy (AFM) and UV-visible absorption techniques. Photocatalytic activity of the coatings was determined by photomineralisation of stearic acid under 254, 365 nm and white light sources monitored by FT-IR spectroscopy.